Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 145

1.

Jupiter microtubule-associated homolog 1 (JPT1): A predictive and pharmacodynamic biomarker of metformin response in endometrial cancers.

Bateman NW, Teng PN, Hope E, Hood BL, Oliver J, Ao W, Zhou M, Wang G, Tommarello D, Wilson K, Litzy T, Conrads KA, Hamilton CA, Darcy KM, Casablanca Y, Maxwell GL, Bae-Jump V, Conrads TP.

Cancer Med. 2019 Dec 6. doi: 10.1002/cam4.2729. [Epub ahead of print]

2.

Genomic heterogeneity in peritoneal implants: A differential analysis of gene expression using nanostring Human Cancer Reference panel identifies a malignant signature.

Mhawech-Fauceglia P, Izevbaye I, Spindler T, Wang G, Hwang H, Samrao D, Elishaev E, Maxwell GL, Lawrenson K, Darcy KM.

Gynecol Oncol. 2019 Nov 8. pii: S0090-8258(19)31605-1. doi: 10.1016/j.ygyno.2019.10.021. [Epub ahead of print]

PMID:
31711656
3.

Short-term Quality of Life after Myomectomy for Uterine Fibroids from the Compare-UF Fibroid Registry.

Laughlin-Tommaso SK, Lu D, Thomas L, Diamond M, Wallace K, Wegienka G, Vines A, Anchan R, Wang T, Maxwell GL, Jacoby V, Marsh EE, Spies JB, Nicholson W, Stewart EA, Myers E.

Am J Obstet Gynecol. 2019 Oct 30. pii: S0002-9378(19)31235-9. doi: 10.1016/j.ajog.2019.09.052. [Epub ahead of print]

PMID:
31678093
4.

Nitric Oxide Donor DETA/NO Inhibits the Growth of Endometrial Cancer Cells by Upregulating the Expression of RASSF1 and CDKN1A.

Waheed S, Cheng RY, Casablanca Y, Maxwell GL, Wink DA, Syed V.

Molecules. 2019 Oct 16;24(20). pii: E3722. doi: 10.3390/molecules24203722.

5.

Sixteen year-old with leiomyosarcoma in a prior benign myomectomy site.

Vaz JA, Kashi PK, Movahedi-Lankarani S, Piguet NB, Zeligs KP, Bijelic L, Rao UNM, Conrads TP, Maxwell GL, Darcy KM, Garg R.

Gynecol Oncol Rep. 2019 Aug 19;29:126-129. doi: 10.1016/j.gore.2019.08.002. eCollection 2019 Aug.

6.

Patient preferences for attributes of primary surgical debulking versus neoadjuvant chemotherapy for treatment of newly diagnosed ovarian cancer.

Havrilesky LJ, Yang JC, Lee PS, Secord AA, Ehrisman JA, Davidson B, Berchuck A, Darcy KM, Maxwell GL, Reed SD.

Cancer. 2019 Dec 15;125(24):4399-4406. doi: 10.1002/cncr.32447. Epub 2019 Aug 27.

PMID:
31454432
7.

Prospective Validation of an Ex Vivo, Patient-Derived 3D Spheroid Model for Response Predictions in Newly Diagnosed Ovarian Cancer.

Shuford S, Wilhelm C, Rayner M, Elrod A, Millard M, Mattingly C, Lotstein A, Smith AM, Guo QJ, O'Donnell L, Elder J, Puls L, Weroha SJ, Hou X, Zanfagnin V, Nick A, Stany MP, Maxwell GL, Conrads T, Sood AK, Orr D, Holmes LM, Gevaert M, Crosswell HE, DesRochers TM.

Sci Rep. 2019 Aug 1;9(1):11153. doi: 10.1038/s41598-019-47578-7.

8.

The effect of labor and delivery mode on electrocortical and brainstem autonomic function during neonatal transition.

Mulkey SB, Kota S, Govindan RB, Al-Shargabi T, Swisher CB, Eze A Jr, Hitchings L, Russo S, Herrera N, McCarter R, Maxwell GL, Baker R, du Plessis AJ.

Sci Rep. 2019 Jul 30;9(1):11020. doi: 10.1038/s41598-019-47306-1.

9.

Biomarker panel for early detection of endometrial cancer in the Prostate, Lung, Colorectal, and Ovarian cancer screening trial.

Tarney CM, Wang G, Bateman NW, Conrads KA, Zhou M, Hood BL, Loffredo J, Tian C, Darcy KM, Hamilton CA, Casablanca Y, Lokshin A, Conrads TP, Maxwell GL.

Am J Obstet Gynecol. 2019 Nov;221(5):472.e1-472.e10. doi: 10.1016/j.ajog.2019.06.005. Epub 2019 Jul 4.

PMID:
31279844
10.

Efficient identification of neoantigen-specific T-cell responses in advanced human ovarian cancer.

Liu S, Matsuzaki J, Wei L, Tsuji T, Battaglia S, Hu Q, Cortes E, Wong L, Yan L, Long M, Miliotto A, Bateman NW, Lele SB, Chodon T, Koya RC, Yao S, Zhu Q, Conrads TP, Wang J, Maxwell GL, Lugade AA, Odunsi K.

J Immunother Cancer. 2019 Jun 20;7(1):156. doi: 10.1186/s40425-019-0629-6.

11.

Reducing Perineal Lacerations Through Team-Based Simulation.

Marko EK, Fausett MB, Deering S, Staat BC, Stormes S, Freund E, Maxwell GL.

Simul Healthc. 2019 Jun;14(3):182-187. doi: 10.1097/SIH.0000000000000378.

PMID:
31136422
12.

Ancestral characterization of 1018 cancer cell lines highlights disparities and reveals gene expression and mutational differences.

Kessler MD, Bateman NW, Conrads TP, Maxwell GL, Dunning Hotopp JC, O'Connor TD.

Cancer. 2019 Jun 15;125(12):2076-2088. doi: 10.1002/cncr.32020. Epub 2019 Mar 13.

13.

From Discovery to Practice and Survivorship: Building a National Real-World Data Learning Healthcare Framework for Military and Veteran Cancer Patients.

Lee JSH, Darcy KM, Hu H, Casablanca Y, Conrads TP, Dalgard CL, Freymann JB, Hanlon SE, Huang GD, Kvecher L, Maxwell GL, Meng F, Moncur JT, Turner C, Wells JM, Wilkerson MD, Zhu K, Ramoni RB, Shriver CD.

Clin Pharmacol Ther. 2019 Jul;106(1):52-57. doi: 10.1002/cpt.1425. Epub 2019 Apr 29. No abstract available.

14.

Genomic and molecular characterization of preterm birth.

Knijnenburg TA, Vockley JG, Chambwe N, Gibbs DL, Humphries C, Huddleston KC, Klein E, Kothiyal P, Tasseff R, Dhankani V, Bodian DL, Wong WSW, Glusman G, Mauldin DE, Miller M, Slagel J, Elasady S, Roach JC, Kramer R, Leinonen K, Linthorst J, Baveja R, Baker R, Solomon BD, Eley G, Iyer RK, Maxwell GL, Bernard B, Shmulevich I, Hood L, Niederhuber JE.

Proc Natl Acad Sci U S A. 2019 Mar 19;116(12):5819-5827. doi: 10.1073/pnas.1716314116. Epub 2019 Mar 4.

15.

Examining HPV Vaccination Practices and Differences Among Providers in Virginia.

Alcalá HE, Maxwell GL, Lindsay B, Keim-Malpass J, Mitchell EM, Balkrishnan R.

J Cancer Educ. 2018 Dec 5. doi: 10.1007/s13187-018-1455-0. [Epub ahead of print]

PMID:
30520008
16.

Autonomic nervous system depression at term in neurologically normal premature infants.

Mulkey SB, Kota S, Swisher CB, Hitchings L, Metzler M, Wang Y, Maxwell GL, Baker R, du Plessis AJ, Govindan R.

Early Hum Dev. 2018 Aug;123:11-16. doi: 10.1016/j.earlhumdev.2018.07.003. Epub 2018 Jul 17.

17.

The Comparing Options for Management: PAtient-centered REsults for Uterine Fibroids (COMPARE-UF) registry: rationale and design.

Stewart EA, Lytle BL, Thomas L, Wegienka GR, Jacoby V, Diamond MP, Nicholson WK, Anchan RM, Venable S, Wallace K, Marsh EE, Maxwell GL, Borah BJ, Catherino WH, Myers ER.

Am J Obstet Gynecol. 2018 Jul;219(1):95.e1-95.e10. doi: 10.1016/j.ajog.2018.05.004. Epub 2018 May 8.

PMID:
29750955
18.

Racial disparities in molecular subtypes of endometrial cancer.

Dubil EA, Tian C, Wang G, Tarney CM, Bateman NW, Levine DA, Conrads TP, Hamilton CA, Maxwell GL, Darcy KM.

Gynecol Oncol. 2018 Apr;149(1):106-116. doi: 10.1016/j.ygyno.2017.12.009.

PMID:
29605044
19.

Progesterone and calcitriol reduce invasive potential of endometrial cancer cells by targeting ARF6, NEDD9 and MT1-MMP.

Waheed S, Dorjbal B, Hamilton CA, Maxwell GL, Rodriguez GC, Syed V.

Oncotarget. 2017 Nov 28;8(69):113583-113597. doi: 10.18632/oncotarget.22745. eCollection 2017 Dec 26.

20.

Ornithine decarboxylase as a therapeutic target for endometrial cancer.

Kim HI, Schultz CR, Buras AL, Friedman E, Fedorko A, Seamon L, Chandramouli GVR, Maxwell GL, Bachmann AS, Risinger JI.

PLoS One. 2017 Dec 14;12(12):e0189044. doi: 10.1371/journal.pone.0189044. eCollection 2017.

21.

Clinicopathologic characteristics associated with long-term survival in advanced epithelial ovarian cancer: an NRG Oncology/Gynecologic Oncology Group ancillary data study.

Hamilton CA, Miller A, Casablanca Y, Horowitz NS, Rungruang B, Krivak TC, Richard SD, Rodriguez N, Birrer MJ, Backes FJ, Geller MA, Quinn M, Goodheart MJ, Mutch DG, Kavanagh JJ, Maxwell GL, Bookman MA.

Gynecol Oncol. 2018 Feb;148(2):275-280. doi: 10.1016/j.ygyno.2017.11.018. Epub 2017 Nov 28.

22.

The impact of adjuvant vaginal brachytherapy in women with Stage II uterine endometrioid carcinoma: Results of a National Cancer Database analysis.

Lee JK, Ghanem AI, Modh A, Burmeister C, Mahmoud O, Maxwell GL, Elshaikh MA.

Brachytherapy. 2018 Mar - Apr;17(2):319-325. doi: 10.1016/j.brachy.2017.10.011. Epub 2017 Nov 23.

PMID:
29174935
23.

Impact of age at diagnosis on racial disparities in endometrial cancer patients.

Tarney CM, Tian C, Wang G, Dubil EA, Bateman NW, Chan JK, Elshaikh MA, Cote ML, Schildkraut JM, Shriver CD, Conrads TP, Hamilton CA, Maxwell GL, Darcy KM.

Gynecol Oncol. 2018 Apr;149(1):12-21. doi: 10.1016/j.ygyno.2017.07.145. Epub 2017 Aug 8.

24.

Race-specific molecular alterations correlate with differential outcomes for black and white endometrioid endometrial cancer patients.

Bateman NW, Dubil EA, Wang G, Hood BL, Oliver JM, Litzi TA, Gist GD, Mitchell DA, Blanton B, Phippen NT, Tian C, Zahn CM, Cohn DE, Havrilesky LJ, Berchuck A, Shriver CD, Darcy KM, Hamilton CA, Conrads TP, Maxwell GL.

Cancer. 2017 Oct 15;123(20):4004-4012. doi: 10.1002/cncr.30813. Epub 2017 Jun 27.

25.

Establishment and characterization of a platinum- and paclitaxel-resistant high grade serous ovarian carcinoma cell line.

Teng PN, Bateman NW, Wang G, Litzi T, Blanton BE, Hood BL, Conrads KA, Ao W, Oliver KE, Darcy KM, McGuire WP, Paz K, Sidransky D, Hamilton CA, Maxwell GL, Conrads TP.

Hum Cell. 2017 Jul;30(3):226-236. doi: 10.1007/s13577-017-0162-1. Epub 2017 Mar 1.

PMID:
28251557
26.

The promise of molecular staging for the future.

Maxwell GL, Mutch DG.

Cancer. 2017 Mar 1;123(5):728-730. doi: 10.1002/cncr.30504. Epub 2017 Jan 6. No abstract available. Erratum in: Cancer. 2017 Oct 1;123(19):3857.

27.

What is the role of retroperitoneal exploration in optimally debulked stage IIIC epithelial ovarian cancer? An NRG Oncology/Gynecologic Oncology Group ancillary data study.

Rungruang BJ, Miller A, Krivak TC, Horowitz NS, Rodriguez N, Hamilton CA, Backes FJ, Carson LF, Friedlander M, Mutch DG, Goodheart MJ, Tewari KS, Wenham RM, Bookman MA, Maxwell GL, Richard SD.

Cancer. 2017 May 15;123(6):985-993. doi: 10.1002/cncr.30414. Epub 2016 Nov 16.

28.

Interim analysis of a phase I/IIa trial assessing E39+GM-CSF, a folate binding protein vaccine, to prevent recurrence in ovarian and endometrial cancer patients.

Jackson DO, Byrd K, Vreeland TJ, Hale DF, Herbert GS, Greene JM, Schneble EJ, Berry JS, Trappey AF, Clifton GT, Hardin MO, Martin J, Elkas JC, Conrads TP, Darcy KM, Hamilton CA, Maxwell GL, Peoples GE.

Oncotarget. 2017 Feb 28;8(9):15912-15923. doi: 10.18632/oncotarget.13305.

29.

NUAK1 (ARK5) Is Associated with Poor Prognosis in Ovarian Cancer.

Phippen NT, Bateman NW, Wang G, Conrads KA, Ao W, Teng PN, Litzi TA, Oliver J, Maxwell GL, Hamilton CA, Darcy KM, Conrads TP.

Front Oncol. 2016 Oct 27;6:213. eCollection 2016.

30.

Progesterone potentiates the growth inhibitory effects of calcitriol in endometrial cancer via suppression of CYP24A1.

Bokhari AA, Lee LR, Raboteau D, Turbov J, Rodriguez IV, Pike JW, Hamilton CA, Maxwell GL, Rodriguez GC, Syed V.

Oncotarget. 2016 Nov 22;7(47):77576-77590. doi: 10.18632/oncotarget.12725.

31.

Nestin suppression attenuates invasive potential of endometrial cancer cells by downregulating TGF-β signaling pathway.

Bokhari AA, Baker TM, Dorjbal B, Waheed S, Zahn CM, Hamilton CA, Maxwell GL, Syed V.

Oncotarget. 2016 Oct 25;7(43):69733-69748. doi: 10.18632/oncotarget.11947.

32.

Progestins inhibit calcitriol-induced CYP24A1 and synergistically inhibit ovarian cancer cell viability: An opportunity for chemoprevention.

Rodriguez GC, Turbov J, Rosales R, Yoo J, Hunn J, Zappia KJ, Lund K, Barry CP, Rodriguez IV, Pike JW, Conrads TP, Darcy KM, Maxwell GL, Hamilton CA, Syed V, Thaete LG.

Gynecol Oncol. 2016 Oct;143(1):159-167. doi: 10.1016/j.ygyno.2016.04.022. Epub 2016 Jul 29.

PMID:
27106018
33.

An Open Letter to the Food and Drug Administration Regarding the Use of Morcellation Procedures in Women Having Surgery for Presumed Uterine Myomas.

Parker W, Berek JS, Pritts E, Olive D, Kaunitz AM, Chalas E, Clarke-Pearson D, Goff B, Bristow R, Taylor HS, Farias-Eisner R, Fader AN, Maxwell GL, Goodwin SC, Love S, Gibbons WE, Foshag LJ, Leppert PC, Norsigian J, Nager CW, Johnson T, Guzick DS, As-Sanie S, Paulson RJ, Farquhar C, Bradley L, Scheib SA, Bilchik AJ, Rice LW, Dionne C, Jacoby A, Ascher-Walsh C, Kilpatrick SJ, Adamson GD, Siedhoff M, Israel R, Paraiso MF, Frumovitz MM, Lurain JR, Al-Hendy A, Benrubi GI, Raman SS, Kho RM, Anderson TL, Reynolds RK, DeLancey J.

J Minim Invasive Gynecol. 2016 Mar-Apr;23(3):303-8. doi: 10.1016/j.jmig.2015.12.012. Epub 2016 Jan 8. No abstract available.

PMID:
26773577
34.

Identification and functional characterization of a novel bipartite nuclear localization sequence in ARID1A.

Bateman NW, Shoji Y, Conrads KA, Stroop KD, Hamilton CA, Darcy KM, Maxwell GL, Risinger JI, Conrads TP.

Biochem Biophys Res Commun. 2016 Jan 1;469(1):114-119. doi: 10.1016/j.bbrc.2015.11.080. Epub 2015 Nov 22.

PMID:
26614907
35.

Utility of whole-genome sequencing for detection of newborn screening disorders in a population cohort of 1,696 neonates.

Bodian DL, Klein E, Iyer RK, Wong WS, Kothiyal P, Stauffer D, Huddleston KC, Gaither AD, Remsburg I, Khromykh A, Baker RL, Maxwell GL, Vockley JG, Niederhuber JE, Solomon BD.

Genet Med. 2016 Mar;18(3):221-30. doi: 10.1038/gim.2015.111. Epub 2015 Sep 3.

PMID:
26334177
36.

The state of advocacy in cancer.

Maxwell GL.

Gynecol Oncol. 2015 Dec;139(3):573-9. doi: 10.1016/j.ygyno.2015.08.023. Epub 2015 Aug 29. Review.

37.

Reply to G.D. Aletti et al.

Horowitz N, Miller A, Rungruang B, Richard S, Rodriguez N, Bookman MA, Hamilton C, Krivak T, Maxwell GL.

J Clin Oncol. 2015 Oct 20;33(30):3521-2. doi: 10.1200/JCO.2015.62.5707. Epub 2015 Aug 24. No abstract available.

PMID:
26304879
38.

Elevated AKAP12 in paclitaxel-resistant serous ovarian cancer cells is prognostic and predictive of poor survival in patients.

Bateman NW, Jaworski E, Ao W, Wang G, Litzi T, Dubil E, Marcus C, Conrads KA, Teng PN, Hood BL, Phippen NT, Vasicek LA, McGuire WP, Paz K, Sidransky D, Hamilton CA, Maxwell GL, Darcy KM, Conrads TP.

J Proteome Res. 2015 Apr 3;14(4):1900-10. doi: 10.1021/pr5012894. Epub 2015 Mar 19.

39.

Proteomics of the human endometrial glandular epithelium and stroma from the proliferative and secretory phases of the menstrual cycle.

Hood BL, Liu B, Alkhas A, Shoji Y, Challa R, Wang G, Ferguson S, Oliver J, Mitchell D, Bateman NW, Zahn CM, Hamilton CA, Payson M, Lessey B, Fazleabas AT, Maxwell GL, Conrads TP, Risinger JI.

Biol Reprod. 2015 Apr;92(4):106. doi: 10.1095/biolreprod.114.127217. Epub 2015 Feb 18.

PMID:
25695723
40.

Does aggressive surgery improve outcomes? Interaction between preoperative disease burden and complex surgery in patients with advanced-stage ovarian cancer: an analysis of GOG 182.

Horowitz NS, Miller A, Rungruang B, Richard SD, Rodriguez N, Bookman MA, Hamilton CA, Krivak TC, Maxwell GL.

J Clin Oncol. 2015 Mar 10;33(8):937-43. doi: 10.1200/JCO.2014.56.3106. Epub 2015 Feb 9.

41.

Pharmacologic inhibition of ATR and ATM offers clinically important distinctions to enhancing platinum or radiation response in ovarian, endometrial, and cervical cancer cells.

Teng PN, Bateman NW, Darcy KM, Hamilton CA, Maxwell GL, Bakkenist CJ, Conrads TP.

Gynecol Oncol. 2015 Mar;136(3):554-61. doi: 10.1016/j.ygyno.2014.12.035. Epub 2015 Jan 2.

42.

Survival advantage of marriage in uterine cancer patients contrasts poor outcome for widows: a Surveillance, Epidemiology and End Results study.

Lowery WJ, Stany MP, Phippen NT, Bunch KP, Oliver KE, Tian C, Maxwell GL, Darcy KM, Hamilton CA.

Gynecol Oncol. 2015 Feb;136(2):328-35. doi: 10.1016/j.ygyno.2014.12.027. Epub 2014 Dec 26.

PMID:
25546111
43.

Metastatic choriocarcinoma presenting in a gravid woman.

Byrd K, Seay R, Bechert CJ, Maxwell GL, Bicher A.

Gynecol Obstet Invest. 2015;79(4):276-9. doi: 10.1159/000363234. Epub 2014 Nov 19.

PMID:
25412690
44.

MicroRNAs in endometrial cancers from black and white patients.

Maxwell GL, Shoji Y, Darcy K, Litzi T, Berchuck A, Hamilton CA, Conrads TP, Risinger JI.

Am J Obstet Gynecol. 2015 Feb;212(2):191.e1-10. doi: 10.1016/j.ajog.2014.08.028. Epub 2014 Aug 28.

PMID:
25174797
45.

Progesterone inhibits endometrial cancer invasiveness by inhibiting the TGFβ pathway.

Bokhari AA, Lee LR, Raboteau D, Hamilton CA, Maxwell GL, Rodriguez GC, Syed V.

Cancer Prev Res (Phila). 2014 Oct;7(10):1045-55. doi: 10.1158/1940-6207.CAPR-14-0054. Epub 2014 Jul 28.

46.

Current approaches and challenges in managing and monitoring treatment response in ovarian cancer.

Marcus CS, Maxwell GL, Darcy KM, Hamilton CA, McGuire WP.

J Cancer. 2014 Jan 1;5(1):25-30. doi: 10.7150/jca.7810. Review.

47.

Identification of candidate circulating cisplatin-resistant biomarkers from epithelial ovarian carcinoma cell secretomes.

Teng PN, Wang G, Hood BL, Conrads KA, Hamilton CA, Maxwell GL, Darcy KM, Conrads TP.

Br J Cancer. 2014 Jan 7;110(1):123-32. doi: 10.1038/bjc.2013.687. Epub 2013 Oct 31.

48.

Evidence of a chemopreventive effect of progestin unrelated to ovulation on reproductive tract cancers in the egg-laying hen.

Rodriguez GC, Barnes HJ, Anderson KE, Whitaker RS, Berchuck A, Petitte JN, Lancaster JM, Wenham RM, Turbov JM, Day R, Maxwell GL, Carver DK.

Cancer Prev Res (Phila). 2013 Dec;6(12):1283-92. doi: 10.1158/1940-6207.CAPR-12-0426. Epub 2013 Oct 17.

49.

The effectiveness of Soldier Medical Readiness Councils in reducing and shaping the population of soldiers not medically deployable.

Malish RG, Maxwell GL, Arnett AD, Cassidy JM, Place RJ.

Mil Med. 2013 Jul;178(7):715-21. doi: 10.7205/MILMED-D-13-00003.

PMID:
23820343
50.

Upper abdominal procedures in advanced stage ovarian or primary peritoneal carcinoma patients with minimal or no gross residual disease: an analysis of Gynecologic Oncology Group (GOG) 182.

Rodriguez N, Miller A, Richard SD, Rungruang B, Hamilton CA, Bookman MA, Maxwell GL, Horowitz NS, Krivak TC.

Gynecol Oncol. 2013 Sep;130(3):487-92. doi: 10.1016/j.ygyno.2013.06.017. Epub 2013 Jun 17.

PMID:
23791702

Supplemental Content

Loading ...
Support Center